Treatment for relapsed/refractory sickness should be decided according to prior therapy as well as The rationale why the initial therapy was no longer ideal (e.g., refractoriness vs. intolerance). Ibrutinib is the current gold common therapy for patients with relapsed/refractory disease, according to the outcome of various phase I-III trials, one https://situsjudimbl7723455.onesmablog.com/the-single-best-strategy-to-use-for-situs-judi-mbl77-71895630